Less Ads, More Data, More Tools Register for FREE

Pin to quick picksArecor Therape Regulatory News (AREC)

Share Price Information for Arecor Therape (AREC)

Share Price is delayed by 15 minutes
Get Live Data
62.50    0.00 (0.00%)
Bid:
60.00
Ask:
65.00
Spread: 5.00 (8.333%)
Market Cap: £23.60m
AREC Live PriceLast checked at - London Stock Exchange

Intraday Arecor Therape Share Chart

Holding(s) in Company

11 Nov 2025 09:50

RNS Number : 0545H
Arecor Therapeutics PLC
11 November 2025
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

ARECOR THERAPEUTICS PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Lucius Cary

City and country of registered office (if applicable)

Oxford, UK

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

07/11/25

6. Date on which issuer notified (DD/MM/YYYY):

08/11/25

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

5.0%

5.0%

1,904,835

 

Position of previous notification (if

applicable)

3.1%

3.1%

1,171,146

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BMWLM973

1,904,835

 

5.0%

SUBTOTAL 8. A

1,904,835

 

5.0%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting, please identify:

Name of the proxy holder

n/a

The number and % of voting rights held

n/a

The date until which the voting rights will be held

n/a

11. Additional information xvi

Voting rights are held by AJ Bell

 

Place of completion

London

Date of completion

7 November 2025

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBBBLTMTIBMLA
Date   Source Headline
28th May 20262:00 pmRNSResult of AGM
21st May 20261:00 pmRNSGrant of options and PDMR dealing
18th May 20267:00 amRNS-RUpcoming conference attendance
28th Apr 20264:28 pmRNSPosting of Annual Report and Notice of AGMm
13th Apr 20267:00 amRNSFinal Results
30th Mar 20267:00 amRNSNotice of FY25 Results
26th Mar 20267:00 amRNSLigand Pharmaceuticals Milestone Payment
9th Mar 20267:00 amRNS-RArecor to present at Oppenheimer conference
9th Feb 20267:00 amRNS2025 Business Update
6th Jan 20262:01 pmRNSFireside Panel Discussion on Diabetes sector
9th Dec 20257:00 amRNSArecor and Sequel Med Tech to host fireside panel
17th Nov 202511:37 amRNSHolding(s) in Company
11th Nov 20259:50 amRNSHolding(s) in Company
4th Nov 20257:00 amRNSEnhanced IP Coverage: AT278 & Oral Peptide Program
29th Sep 20257:00 amRNSDirectorate Changes
25th Sep 20257:00 amRNSInterim results for the six months to 30 June 2025
25th Sep 20257:00 amRNSCo-Development Agreement & Monetisation Deal
24th Sep 20259:30 amRNSNotice of Interim Results
4th Sep 20257:00 amRNSPositive FDA Feedback on Phase 2 Study Design
28th Aug 202512:00 pmRNSHolding(s) in Company
8th Aug 20257:00 amRNSChange of Auditor
14th Jul 20257:00 amRNS-RArecor Establishes New Scientific Advisory Board
4th Jun 20257:00 amRNSGrant of Options and PDMR Dealing
2nd Jun 20251:32 pmRNSResult of AGM
2nd Jun 20257:00 amRNSNon-Executive Director Board Change
21st May 20257:00 amRNSDirector/PDMR Dealing
19th May 20257:00 amRNSArecor Partnership with Skye Bioscience
14th May 20252:37 pmRNSDirector Dealing
8th May 20257:00 amRNSArecor sells rights to non-Ogluo® products
6th May 20254:42 pmRNSPosting of 2024 Annual Report and Notice of AGM
24th Apr 20257:00 amRNS-RArecor to present on Investor Meet Company
23rd Apr 20257:00 amRNSGrant of Options and PDMR Dealing
22nd Apr 20257:00 amRNSFinal results for 2024
10th Apr 20257:00 amRNSNotice of Results
26th Mar 20257:00 amRNSCollaboration with global pharmaceutical partner
12th Mar 20257:00 amRNSArecor partnership with biopharmaceutical company
3rd Feb 20257:00 amRNSArecor Full Year 2024 Trading Update
10th Jan 20257:45 amRNSOrderly Cessation of Tetris Pharma Operations
9th Jan 20257:00 amRNSChange of Nominated Advisor and Joint Broker
30th Dec 20247:00 amRNSArecor Signs Exclusive Licensing Agreement
2nd Dec 20247:00 amRNSGrant of Options and PDMR Dealing
18th Nov 20247:00 amRNSArecor Appoints Interim Chief Financial Officer
26th Sep 20247:00 amRNSInterim Results for six months ended 30 June 2024
19th Sep 20243:17 pmRNSNotice of Results
11th Sep 20247:00 amRNSArecor presents positive AT278 data at EASD
22nd Aug 20244:34 pmRNSHolding(s) in Company
20th Aug 20241:44 pmRNSHolding(s) in Company
12th Aug 20243:02 pmRNSHolding(s) in Company
8th Aug 20242:48 pmRNSResult of General Meeting and Total Voting Rights
23rd Jul 20244:26 pmRNSPosting of Circular and General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.